Conceptus (NASDAQ: CPTS) CEO InterviewConceptus (NASDAQ: CPTS) CEO InterviewThis interview has expired. Special deals for our readers Be a more profitable investor: Get an Equifax 3-in-1 Credit Report Now! Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing. Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition! LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount. Get FICO Score Watch Now! Click here to get access to powerful investing tools only available at Investor’s Business Daily. Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here
Conceptus Conceptus, Inc. develops, manufactures and markets the Essure permanent birth control system, a medical device for women that is approved for marketing in the United States by the United States Food and Drug Administration (FDA). The Essure system uses a soft and flexible micro-insert that is delivered into a woman’s fallopian tubes to provide permanent birth control by causing benign tissue in-growth that blocks the fallopian tubes. A properly placed Essure micro-insert and the subsequent tissue growth prohibits the egg from traveling through the fallopian tubes and therefore prevents fertilization. On January 7, 2008, the Company acquired all of the outstanding shares of Conceptus SAS. Through Conceptus SAS, it sells Essure directly in France and uses distributors to sell Essure throughout the rest of Europe. Leave a Reply |
|
WSR Recommends |
||
| Special Deal for Our Readers (That’s You!) | Jim Cramer: The Clown That Makes You Money | Get Rich with Fibonacci. Learn How to Use Fibonacci Analysis to Trade Better. |
